Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Classic Psychedelic or Dissociative or [[:Category:Incretin_modulators|Incretin pathway modulator]]

Use the filters below to narrow your results.

generic:
brand:
None (86) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Januvia; with metformin Janumet/Janumet XR (1) · Spravato (1) · Tradjenta; with metformin Jentadueto (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · NMDA antagonist (3) · None (2) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)
uses:
None (89) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-00000764-QINU`"' (1) · '"`UNIQ--vote-0000117B-QINU`"' (1)
starting dose:
None (89) · 100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) · 5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (89) · 25, 50, 100 mg tablets; combination tablets with metformin (1) · 28 mg/device (each dose uses 2 devices) (1) · 5 mg tablets; combination with metformin (1)
fda max:
None (89) · 100 mg/d (1) · 5 mg/d (1) · 84 mg per session (1)
routes:
None (88) · Intranasal (under direct medical supervision) (1) · Oral (3)
onset:
None (88) · 30–60 minutes (1) · Postprandial glucose effect within days; HbA1c by 12 weeks (2) · Within hours of first administration (1)
duration:
None (88) · 24 hours (2) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)
halflife:
None (88) · 3–5 hours (1) · ~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) · ~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) · ~7-12 hours (1)
bioavailability:
None (88) · 70–90% (oral) (1) · ~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) · ~48% intranasal (1) · ~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)
pregnancy:
None (88) · Avoid; may cause fetal harm (1) · Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Not established (1)
legal:
None (88) · Rx, Schedule III (US). REMS program required. (1) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 92 results in range #1 to #92.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"